Enliven Therapeutics, Inc. (ELVN) Insider Trading -- Recent Executive & Director Transactions
12 insiders reported 175 Form 4 transactions for Enliven Therapeutics, Inc. (ELVN) over the past 18 months (most recent 2026-10-05). Recent activity: Garland J. Scott (Director) Sell 13,000 shares, Garland J. Scott (Director) Buy 13,000 shares, Collins Helen Louise (CHIEF MEDICAL OFFICER) Buy 5,000 shares, Hohl Benjamin (CHIEF FINANCIAL OFFICER) Buy 3,982 shares, Collins Helen Louise (CHIEF MEDICAL OFFICER) Sell 2,916 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Garland J. Scott | Director | Sell | 13,000 | $606,719 |
| 2026-10-05 | Garland J. Scott | Director | Buy | 13,000 | $201,110 |
| 2026-09-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Buy | 5,000 | $12,400 |
| 2026-09-21 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Buy | 3,982 | $59,133 |
| 2026-09-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2,916 | $145,891 |
| 2026-09-21 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3,535 | $176,851 |
| 2026-09-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 1,844 | $93,507 |
| 2026-09-21 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 2,194 | $111,270 |
| 2026-09-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 240 | $12,356 |
| 2026-09-21 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 289 | $14,881 |
| 2026-08-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 3,900 | $227,650 |
| 2026-08-19 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 4,630 | $270,168 |
| 2026-08-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Buy | 5,000 | $12,400 |
| 2026-08-19 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 1,388 | $82,383 |
| 2026-08-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 1,100 | $65,281 |
| 2026-08-06 | Derynck Mika K | Director | Buy | 87,373 | $216,685 |
| 2026-08-06 | Derynck Mika K | Director | Buy | 27,567 | $696,894 |
| 2026-08-06 | Derynck Mika K | Director | Buy | 23,364 | $346,955 |
| 2026-08-06 | Derynck Mika K | Director | Buy | 20,491 | $460,433 |
| 2026-08-06 | Derynck Mika K | Director | Sell | 158,795 | $9.6M |
| 2026-07-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Buy | 5,000 | $12,400 |
| 2026-07-21 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Buy | 1,072 | $2,659 |
| 2026-07-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 231 | $11,563 |
| 2026-07-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 459 | $23,660 |
| 2026-07-21 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 324 | $16,191 |
Source: SEC Form 4 filings · as of 2026-10-05